Acute Lymphoblastic Leukemia in Children: Recent Findings
THURSDAY, SEPT. 11, 2014
Nobuko Hijiya, MD, Ann & Robert H. Lurie Children’s Hospital of Chicago
ALL is the most common cancer in children and is among the most curable of the pediatric malignancies. Many clinical, biological, genetic, and molecular features have been identified as having prognostic significance in the outcome of patients with ALL. Prognostic features play a critical role in directing therapy for ALL and as scientific and treatment advances are made, this area of investigation changes rapidly. This session will discuss the importance of prognostic factors that may influence the treatments used for patients with ALL, as well as review treatment protocols designed to reduce toxicity while preserving efficacy for ALL patients.
- Identify prognostic factors that influence treatment and outcomes for patients with ALL.
- Discuss treatment protocols designed to reduce toxicity while preserving efficacy for patients with ALL.
These materials are intended ONLY for pharmacists and pharmacy technicians that attended the presentation, "Acute Lymphoblastic Leukemia in Children: Recent Findings" held at 10:45 a.m. Thur., Sept. 11, 2014. This session was part of the "23rd Annual National Conference" held in Chicago, Ill. on Sept. 10-12, 2014.
The prerequisite to this process is completing the 23rd Annual National Conference Post-Assessment and Evaluation. If there is a Prerequisite section above and the Status field is blank, click on '23rd Annual National Conference' to open the Assessment and Evaluation.
- 0.75 ACPE - Pharmacists